Skip to search formSkip to main contentSkip to account menu

AL3810

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lucitanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
An open-label phase Ib study to determine safety and preliminary efficacy of oral Lucitanib (AL3810) in patients with locally advanced or metastatic gastric, hepatocellular, nasopharyngeal carcinoma…
e15502Background: Angiogenesis is an essential prerequisite for tumor growth, invasion and metastasis. Targeting tumor… 
2015
2015
126OA phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors
2013
2013
Anti-tumor effects of AL3810 on A549 human lung adenocarcinoma
Objective To test the anti-tumor effect of AL3810 on A549 human lung adenocarcinoma.Methods ①The antiproliferative effects of… 
2012
2012
AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
Angiogenesis plays an important role in neoplastic transformation and progression as well as in the metastasis process of most… 
2012
2012
Is PDGFR an important target for E-3810?
Dear Sir, In the issue Journal of Cellular and Molecular Medicine, Zhou et al. [1] reported the preclinical characterization… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)